ABSTRACT
PURPOSE: To evaluate the efficacy of lidocaine tape in reducing pain during botulinum toxin injection. DESIGN: Randomized double-blind study. METHOD: Six men and four women with a diagnosis of Meige syndrome undergoing botulinum toxin injection were recruited. Lidocaine tape was applied to the eyelid skin of a randomly selected eye and placebo tape to the other eye. Pain during botulinum toxin injection was evaluated subjectively by a visual analogue scale. Side effects were also monitored. RESULTS: Mean subjective pain both on puncturing skin and on injection in the lidocaine group was significantly lower than that in the placebo group. Nine of 10 patients found lidocaine tape to be more effective than placebo tape in reducing pain during injection. CONCLUSIONS: Lidocaine tape is a simple and convenient method of reducing pain during botulinum toxin injection. This method is recommended for patients reluctant to receive this treatment because of pain during injection.
Subject(s)
Anesthetics, Local/administration & dosage , Botulinum Toxins, Type A/therapeutic use , Lidocaine/administration & dosage , Meige Syndrome/drug therapy , Neuromuscular Agents/therapeutic use , Pain/prevention & control , Anesthesia, Local/methods , Double-Blind Method , Female , Humans , Injections , Male , Middle Aged , Oculomotor Muscles/drug effects , Pain Measurement , Palliative Care/methodsSubject(s)
Meige Syndrome/diagnosis , Psychophysiologic Disorders/diagnosis , Stress, Psychological/complications , Amitriptyline/administration & dosage , Baclofen/administration & dosage , Clonazepam/administration & dosage , Drug Therapy, Combination , Female , Humans , Meige Syndrome/drug therapy , Meige Syndrome/etiology , Meige Syndrome/psychology , Middle Aged , Nifedipine/administration & dosage , Psychophysiologic Disorders/drug therapy , Psychophysiologic Disorders/etiologyABSTRACT
Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.